FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
FTC: Big 3 PBMs generated $7.3B from specialty generic drug markups
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal Trade Commission (FTC) uncovered in its second interim staff report rele | The FTC released its second interim staff report Tuesday during Chair Lina Khan's final open commission meeting,
FTC takes fresh swipe at drug middlemen, says some prices marked up over 1,000%
The drug middlemen known as pharmacy-benefit managers took another body blow from regulators on Tuesday, as they were criticized for charging way more for some “critical” prescription drugs than it cost them.
FTC says pharmacy benefits managers marked-up generic drug prices for $7.3bn gain
Regulator’s report finds companies ‘hiked costs’ for a range of medicines, including cancer and HIV treatments
Largest Pharmacy-Benefit Managers Hiked Up Drug Prices, FTC Says
The largest pharmacy-benefit managers hiked the prices of certain drugs dispensed through their own pharmacies, according to a new report by the Federal Trade Commission released on Tuesday. The markups helped the PBMs reap $7.
STAT1d
Will PBM reform save pharmacies from closing?
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
pharmaphorum1d
FTC doubles down on PBM criticism in new report
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Forbes1mon
Does PBM Expansion Into Drug Manufacturing Benefit Patients Or Risk Further Anti-Competitive Behaviors?
CVS Health’s PBM might influence which drugs are promoted and covered, potentially preferring Cordavis’ products over others. The result would stifle market competition. Patient steerage to ...
Hosted on MSN20h
FTC Report Reveals PBM Practices Impacting Competition and Drug Costs
The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...
The Hill27d
House GOP drops PBM reforms in scaled-down spending bill
House Republicans have abandoned language to rein in the pharmacy benefit manager (PBM) industry from a new government funding bill released late Thursday. Leaders earlier this week agreed to PBM ...
Forbes2mon
Rebate Game Played By PBMs And Drug Makers Limits Biosimilar Competition
which is the PBM’s specialty pharmacy. What CVS Caremark and Express Scripts are doing is (mostly) steering patients to their preferred products, which aren’t necessarily the least expensive.
STAT28d
House Republicans abandon PBM reform in push to keep government open
WASHINGTON — House Republicans have abandoned an effort to include reforms to pharmacy benefit managers in an end-of-year bill to fund the federal government. Congressional leaders had reached ...
Drug Store News27d
Pharmacy groups to “key vote” continuing resolution with PBM reforms
“PBM tactics inflate American’s prescription drug costs, force pharmacy closures, and block access to Americans’ pharmacies of choice. The work done by Congress in the 118th Congress and in ...
Benefits Pro25d
President signs anti-shutdown package, with no PBM provisions
Ron Wyden says Elon Musk, an advisor to President Donald Trump who's on track to lead a new Department of Government Efficiency, pushed the PBM provisions out of the package. The new American ...